 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 August 1997 | Volume 127 Issue 4 | Pages 281-284
Background: The risks of antiarrhythmic therapy are increasingly recognized, but the risks associated with the initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation are poorly defined.
Objective: To determine the incidence, time course, and predictors of adverse cardiac events that require intervention during initiation of antiarrhythmic drug therapy for atrial fibrillation.
Design: Retrospective chart review.
Setting: University hospital.
Participants: 417 consecutive patients who underwent a total of 597 drug trials during a total of 550 hospitalizations for atrial fibrillation.
Intervention: Initiation of therapy with antiarrhythmic drugs: procainamide (189 trials), quinidine (179 trials), disopyramide (20 trials), propafenone (110 trials), flecainide (2 trials), sotalol (72 trials), and amiodarone (25 trials). Electrical conversion was performed during 247 trials.
Measurements: Incidence of adverse events and daily hazard rate were measured. Logistic regression was done to identify risk factors.
Results: During the 597 drug trials, 80 (13.4%) cardiac adverse events occurred in 73 patients. The risk was greatest during the first 24 hours of therapy. Bradyarrhythmias were the most common adverse event, occurring in 47 trials (7.9%); prolongation of the QT interval warranting discontinuation of drug therapy (9 trials; 1.5%) and ventricular arrhythmias (8 trials; 1.3%) were less frequent. In multivariate analysis, previous myocardial infarction was associated with increased risk (odds ratio, 1.90 [95% CI, 1.05 to 3.43]) and the association between older age and increased risk (odds ratio, 1.29 per decade [CI, 0.97 to 1.72]) was of borderline statistical significance.
Conclusions: A significant risk for cardiac adverse events exists during initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation. Observation with electrocardiographic monitoring seems advisable for 24 to 48 hours during initiation of antiarrhythmic therapy, particularly for elderly patients and patients who have previously had myocardial infarction.
Author and Article Information
From Brigham and Women's Hospital, Boston, Massachusetts.
ARTICLE
Risk of Initiating Antiarrhythmic Drug Therapy for Atrial Fibrillation in Patients Admitted to a University Hospital
Requests for Reprints: William G. Stevenson, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115.
Current Author Addresses: Drs. Maisel, Reimold, Antman, Friedman, and Stevenson: Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115.
This article has been cited by other articles:
|
|
 |
|
  V. Essebag, M. R. Reynolds, T. Hadjis, R. Lemery, B. Olshansky, A. E. Buxton, M. E. Josephson, and P. Zimetbaum Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation Arch Intern Med, August 13, 2007; 167(15): 1648 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Sherrid, I. Barac, W. J. McKenna, P. M. Elliott, S. Dickie, L. Chojnowska, S. Casey, and B. J. Maron Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1251 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fetsch, P. Bauer, R. Engberding, H. P. Koch, J. Lukl, T. Meinertz, M. Oeff, L. Seipel, H. J. Trappe, N. Treese, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial Eur. Heart J., August 2, 2004; 25(16): 1385 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography Ann Intern Med, December 16, 2003; 139(12): 1018 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Tejan-Sie, R. D. Murray, I. W. Black, S. E. Jasper, C. Apperson-Hansen, J. Li, E. A. Lieber, R. A. Grimm, A. L. Klein, and ACUTE Investigators Spontaneous conversion of patients with atrial fibrillation scheduled for electrical cardioversion: An ACUTE trial ancillary study J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1638 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Al-Khatib, N. M. A. LaPointe, J. M. Kramer, and R. M. Califf What Clinicians Should Know About the QT Interval JAMA, April 23, 2003; 289(16): 2120 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Essebag, T. Hadjis, R. W. Platt, and L. Pilote Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction J. Am. Coll. Cardiol., January 15, 2003; 41(2): 249 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Aronow Management of the Older Person With Atrial Fibrillation J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M352 - 363. [Abstract] [Full Text]
|
|
|
|
|
|
W. H. Maisel, J. D. Rawn, and W. G. Stevenson Atrial Fibrillation after Cardiac Surgery Ann Intern Med, December 18, 2001; 135(12): 1061 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Reiffel and G. Appel Importance of QT Interval Determination and Renal Function Assessment During Antiarrhythmic Drug Therapy Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 111 - 119. [Abstract] [PDF]
|
|
|
|
|
|
G. Cotter, A. Blatt, E. Kaluski, E. Metzkor-Cotter, M. Koren, I. Litinski, R. Simantov, Y. Moshkovitz, R. Zaidenstein, E. Peleg, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study Eur. Heart J., December 2, 1999; 20(24): 1833 - 1842. [Abstract] [PDF]
|
|
|
|
 |
|
 A E Tuinenburg, I C Van Gelder, M P V. Den Berg, J Brugemann, P J De Kam, and H J G M Crijns Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation Heart, October 1, 1999; 82(4): 486 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Catherwood, W. D. Fitzpatrick, M. L. Greenberg, P. T. Holzberger, D. J. Malenka, B. R. Gerling, and J. D. Birkmeyer Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation Ann Intern Med, April 20, 1999; 130(8): 625 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Grace and A. J. Camm Quinidine N. Engl. J. Med., January 1, 1998; 338(1): 35 - 45. [Full Text] [PDF]
|
|
Article
